Top Line: BioTissue has unveiled CAM360 AminoGraft, (CAM360 AG), a new, hydrated, shelf-stable Cryopreserved Amniotic Membrane (CAM) solution that was developed to optimize comfort.
Close Up: Ideal for patients who have mild to moderate dry eye disease and other ocular surface conditions, CAM360 AG is a ringless CAM that does not require refrigeration, the company said. Its adhesive properties ensure that the CAM stays in place under a Bandage Contact Lens (BCL).
Ted Davis, president and CEO, BioTissue, said, “The introduction of CAM360 AG revolutionizes how eyecare professionals can leverage regenerative medicine in the treatment of the ocular surface, particularly when it comes to Dry Eye Disease. Dry Eye Disease is a progressive disease, and until now, the lack of options available meant that practitioners often had to wait until the patient’s condition worsened before they could intervene. CAM360 AG bridges that gap, enabling practitioners to provide more patients with treatment much earlier, which is a true reflection of our dedication to improving patients’ lives with everything we do.”
Vital Stats: BioTissue says that CAM products have been proven to alleviate signs and symptoms of Dry Eye Disease, and its unique composition exerts potent anti-inflammatory, anti-scarring, and anti-angiogenic actions that help promote the body’s healing capabilities. It is adaptable to treat many conditions including mild to moderate Dry Eye Disease, superficial punctate keratitis, neurotrophic keratitis and more. BioTissue has provided treatment to more than 900,000 patients, with its scientific and clinical breakthroughs documented in more than 400 peer-reviewed publications.
biotissue.com